JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	733
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	423
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	109
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	106
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	96
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	82
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	79
Herpes zoster and dementia : more evidences for a causal link	68
Gene and genetic therapies in Alzheimer’s disease and other dementias	60
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	50
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	47
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	46
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	41
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	38
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	38
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	38
Informal care for people with dementia in Europe	37
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	37
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	36
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	36
Introduction to the Special Issue on the A4 Study	32
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	30
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	30
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	27
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	26

Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	26
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	24
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	23
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	22
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	22
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	22
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	21
Donanemab: Appropriate use recommendations	21
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	21
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	20
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	20
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	20
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	20
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	20
Editorial Board	19
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease	19
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	19
Treatments for Alzheimer’s and the declaration of Helsinki	18
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	18
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	17
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	17
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	17
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	17
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	16
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	16
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	16
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	16
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	16
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	16
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	16
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	16
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	16
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	15
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy	15
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	15
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	15
Where Do We Go from Here?	14
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	14
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	14
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	14
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	14
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	13
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	13
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	13
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	13
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	13
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	13
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	13
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	13
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	12

Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	12
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	12
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	12
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	12
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabece	12
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	12
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	12
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	12
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	12
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review	12
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	12
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	11
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	11
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	11
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	11
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	11
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	11
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	11
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	11
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	11
The ‘Aducanumab Story': Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis' or Mark a New Beginning?	11
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	11
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	10
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	10
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	10
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	10
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective	10
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	10
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland	10
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	10
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	10
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis	10
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	10
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	10
Posters	10
Editorial Board	10
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	10
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	10
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	10
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	10
Symposia — Oral Communications — Late Breaking News	10
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	9
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	9
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	9
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	9
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	9
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	9
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	9
Alzheimer’s disease prevention by flavonols and their analogs	9
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	9
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials	9
Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	9
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	9
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	9
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	9
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	9
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	9
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	8
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	8
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	8
Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	8
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	8
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	8
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	8
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	8
The Future is Now: Advancing Blood-Based Markers	8
The Dawn of a New Era of Alzheimer's Research and Drug Development	8
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	8
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	8
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	8
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	8
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	8
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	8
Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial	8
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	8
Eligibility for donanemab trial in a population-based study of cognitive aging	7
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	7
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	7
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	7
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	7

Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis	7
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	7
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	7
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	7
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	7
Early-Onset Type 2 Diabetes and Risk of Dementia	7
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	7
Microglial activation states and their implications for Alzheimer's Disease	7
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	7
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	7
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	7
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	7
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	7
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research	7
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	7
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	7
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	7
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	7
Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review	7
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	7
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	7
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	7